Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas

Complete resection of invasive pituitary adenoma is usually difficult, resulting in a high recurrence rate. Therefore, it is needed to find potential diagnostic markers and therapeutic targets for invasive pituitary adenoma.We collected samples from patients with invasive and non-invasive pituitary adenomas from Beijing Tiantan Hospital for protein extraction and quantitative analysis. We identified differential proteins (DEPs) by differential analysis of the two groups. The intersection of differential proteins related to invasion and epithelial-mesenchymal transition (EMT) in the GeneCards database was identified as EMT-DEPs. The protein network of EMT-DEPs was analyzed using the STRING database and Cytoscape software, and the hub EMT-DEPs were obtained by the MCC algorithm of the cytoHubba plugin. Correlation analysis was used to obtain the interpairing proteins among EMT-DEPs, and core EMT-DEPs were identified based on the number of paired proteins. The Venn program was used to identify the intersection of hub EMT-DEPs and core EMT-DEPs as key EMT-DEPs. Finally, a series of analyses plus experiments were used to verify the correlation of the target protein with invasion and EMT in pituitary adenoma.Quantitative comparison of proteins between invasive and non-invasive pituitary adenomas indicated 833 differential proteins. The overlaps of EMT-related proteins and differential proteins consisted of 46 EMT-DEPs. There were 6 intersections between the hub EMT-DEPs and core EMT-DEPs. Using quantitative protein data and GSE169498 chip, we found that solute carrier family 2 member 1 (SLC2A1) was our target protein. SLC2A1 was significantly correlated with the invasiveness of pituitary adenoma, and the ROC curve was satisfactory. The functions and pathways of SLC2A1 and paired protein enrichment were closely linked to the EMT. Consistently, SLC2A1 expression was significantly and positively correlated with the expression of classical markers of EMT. The final experiment revealed that SLC2A1 was significantly upregulated in invasive pituitary adenoma.SLC2A1 is significantly upregulated in invasive pituitary adenoma with satisfactory predictive value. It may regulate EMT. It may be a potential diagnostic marker for invasive pituitary adenoma.

[1]  M. Khamseh,et al.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma , 2022, Endocrine.

[2]  Suray Pehlivanoglu,et al.  Epithelial mesenchymal transition regulator TWIST1 transcription factor stimulates glucose uptake through upregulation of GLUT1, GLUT3, and GLUT12 in vitro , 2021, In Vitro Cellular & Developmental Biology - Animal.

[3]  Jianhua Cheng,et al.  Research advances on the immune research and prospect of immunotherapy in pituitary adenomas , 2021, World Journal of Surgical Oncology.

[4]  M. Fleseriu,et al.  The journey in diagnosis and treatment, from pituitary adenoma to aggressive pituitary tumors , 2020, Reviews in Endocrine and Metabolic Disorders.

[5]  Jinxue Zhang,et al.  LAIR-1 overexpression inhibits epithelial–mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism , 2020, World Journal of Surgical Oncology.

[6]  C. Stratakis,et al.  Aggressive pituitary tumors in the young and elderly , 2020, Reviews in Endocrine and Metabolic Disorders.

[7]  Maria M. M. Santos,et al.  SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner , 2020, International journal of molecular sciences.

[8]  Mingwei Liu,et al.  Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma , 2019, Nature.

[9]  A. Grossman,et al.  Aggressive and malignant pituitary tumours: state-of-the-art. , 2018, Endocrine-related cancer.

[10]  P. Delgado-López,et al.  Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options , 2018, Clinical and Translational Oncology.

[11]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. , 2018, European journal of endocrinology.

[12]  M. Lopes,et al.  The 2017 World Health Organization classification of tumors of the pituitary gland: a summary , 2017, Acta Neuropathologica.

[13]  Chengwu Tang,et al.  Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer , 2017, Oncotarget.

[14]  J. Chen,et al.  GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma , 2016, PloS one.

[15]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[16]  T. Tsakiridis,et al.  Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. , 2016, Metabolism: clinical and experimental.

[17]  Ge-bo Wen,et al.  Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT , 2016, Medical Oncology.

[18]  A. Krook,et al.  TWIST1 and TWIST2 regulate glycogen storage and inflammatory genes in skeletal muscle. , 2015, The Journal of endocrinology.

[19]  T. Maeda,et al.  Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model , 2014, Cancer Cell International.

[20]  M. Bryś,et al.  Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis , 2014, Tumor Biology.

[21]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[22]  A. Gao,et al.  Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. , 2014, Endocrine-related cancer.

[23]  P. Grigsby,et al.  AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake , 2014, PloS one.

[24]  A. Levine,et al.  Tumor-Associated Mutant p53 Drives the Warburg Effect , 2013, Nature Communications.

[25]  B. Thorens,et al.  The SLC2 (GLUT) family of membrane transporters. , 2013, Molecular aspects of medicine.

[26]  V. Brunton,et al.  E-cadherin–integrin crosstalk in cancer invasion and metastasis , 2013, Journal of Cell Science.

[27]  P. Vaupel,et al.  Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix , 2013, British Journal of Cancer.

[28]  Su-Ping Chen,et al.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. , 2013, Oncology letters.

[29]  Jun Fan,et al.  Effect on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2 cell line by antisense glucose transporter-1. , 2012, Archives of Medical Research.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  Angélica Figueroa,et al.  Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy , 2010, International journal of endocrinology.

[32]  Z. Werb,et al.  Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. , 2010, Cancer research.

[33]  H. Gaisano,et al.  Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/MMP-2. , 2010, Biochemical and biophysical research communications.

[34]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[35]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[36]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[37]  G. Kroemer,et al.  The Warburg Effect Suppresses Oxidative Stress Induced Apoptosis in a Yeast Model for Cancer , 2009, PloS one.

[38]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[39]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[40]  D. Bowden,et al.  Differential expression of facilitative glucose transporters in normal and tumour kidney tissues , 2007, BJU international.

[41]  P. Maini,et al.  Metabolic changes during carcinogenesis: potential impact on invasiveness. , 2007, Journal of theoretical biology.

[42]  L. Xi,et al.  Inhibition of PC cell-derived growth factor (PCDGF)/granulin-epithelin precursor (GEP) decreased cell proliferation and invasion through downregulation of cyclin D and CDK 4 and inactivation of MMP-2 , 2007, BMC Cancer.

[43]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[44]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[45]  S. Ashley,et al.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. , 2004, Surgery.

[46]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[47]  S. Ito,et al.  Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. , 2002, Journal of the National Cancer Institute.

[48]  J. Weinberg,et al.  GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. , 2000, American journal of physiology. Endocrinology and metabolism.

[49]  E. Robin,et al.  Coordinate regulation of glycolysis by hypoxia in mammalian cells , 1984, Journal of cellular physiology.

[50]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.